Clinical Trials Logo

Filter by:
NCT ID: NCT05917106 Recruiting - Clinical trials for Renal Cell Carcinoma

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Start date: December 26, 2022
Phase:
Study type: Observational [Patient Registry]

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

NCT ID: NCT05916781 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Start date: July 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to determine whether mycophenolate mofetil(MMF) combined with tacrolimus(TAC) can maintain remission in patients with lupus nephritis (LN) who have reached treatment targets after steroid tapering. The main question[s] it aims to answer are: - The efficacy, safety and tolerability of MMF combined with TAC regimen in the treatment of LN patients in the maintenance period. - The influence of low-dose steroid on carotid intima thickness (CIMT). - The omics and cell-free RNA (cfRNA) spectral differences related to lupus flare. - The differences in health economics between steroid tapering and steroid maintenance patients. Participants will be randomly assigned into 2 groups. In the steroid tapering group, participants will take MMF+TAC treatment without steroid for 1 year, and participants who stop steroid treatment without lupus flare will be randomly assigned to monotherapy with MMF or TAC. In the steroid maintenance group, participants will take MMF+TAC+steroid for 1 year, and participants without lupus flare will be randomly assigned to therapy with MMF + steroid or TAC + steroid.

NCT ID: NCT05916573 Completed - Renal Impairment Clinical Trials

A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment

Start date: December 12, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of HSK16149 in subjects with mild, moderate and severe renal impairment compared to the matched control subjects with normal renal function.

NCT ID: NCT05916547 Recruiting - Clinical trials for Pancreatic Duct Stone

Safety and Efficacy of Extracorporeal Shock Wave Lithotripsy for Pancreatic Stones

Start date: June 27, 2023
Phase:
Study type: Observational

To determine the types, incidence and risk factors of adverse events after pancreatic extracorporeal shock wave lithotripsy (P-ESWL), define the grading criteria of adverse events after P-ESWL, and analyze the efficacy of P-ESWL, which will provide evidence-based medical evidence to guide physicians' clinical practice.

NCT ID: NCT05916391 Recruiting - Clinical trials for Diabetic Macular Edema

Gene Therapy for Diabetic Macular Edema

Start date: May 19, 2023
Phase: Phase 1
Study type: Interventional

FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic macular edema is the main cause of vision loss in patients with diabetic retinopathy. In the latest guidelines, anti-VEGF therapy is preferred for CI-DME. Administration of FT-003 has the potential to treat CI-DME by providing intraocular protein which is durable expressed in therapeutic level. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with CI-DME receiving anti-VEGF therapy in clinical practice.

NCT ID: NCT05916261 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

Start date: April 26, 2023
Phase: Early Phase 1
Study type: Interventional

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

NCT ID: NCT05916248 Recruiting - Clinical trials for Advanced Solid Tumor

Personalized Tumor Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Start date: May 18, 2023
Phase: Phase 1
Study type: Interventional

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of advanced solid tumors. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

NCT ID: NCT05916014 Recruiting - Clinical trials for Artificial Intelligence

AI-assisted White Light Endoscopy to Identify the Kimura-Takemoto Classification of Atrophic Gastritis

Start date: June 1, 2023
Phase:
Study type: Observational

Grading endoscopic atrophy according to the Kimura-Takemoto classification can assess the risk of gastric neoplasia development. However, the false negative rate of chronic atrophic gastritis is high due to the varying diagnostic standardization and diagnostic experience and levels of endoscopists. Therefore, this study aims to develop an AI model to identify the Kimura-Takemoto classification.

NCT ID: NCT05915923 Recruiting - Clinical trials for Transcranial Magnetic Stimulation

Effect of Transcranial Magnetic Stimulation on Dynamic Cerebral Autoregulation in Healthy Adults

Start date: August 2, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of transcranial magnetic stimulation with different stimulation modes ( 1Hz, 10Hz, sham stimulation ) on cerebral autoregulation.

NCT ID: NCT05915871 Completed - Healthy Clinical Trials

Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin

Start date: March 23, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetic interaction between tegoprazan and combination of Amoxicillin, Clarithromycin and bismuth in healthy adult volunteers.